Mapping of Current Obstacles for Rationalizing Use of Medicines (CORUM) in Europe: Current Situation and Potential Solutions.
Europe
health authorities
health technology assessment
initiatives
rational use of medicines
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
25
10
2019
accepted:
04
02
2020
entrez:
21
3
2020
pubmed:
21
3
2020
medline:
21
3
2020
Statut:
epublish
Résumé
There are increasing concerns regarding the inappropriate use of medicines with expenditure continuing to grow driven by increasing sales in oncology and orphan diseases, enhanced by their emotive nature. As a result, even high income countries are struggling to fund new premium priced medicines. These concerns have resulted in initiatives to better manage the entry of new medicines and enhance the rational use of medicines (RUM). However, there is a need to ascertain the current situation. We sought to address this by developing the Current Obstacles for Rationalizing Use of Medicines in Europe (CORUM) mapping tool to qualitatively investigate the current situation and provide analysis of current views on RUM and interventions among key European payers and their advisers. The findings will be used to provide future guidance. Descriptive study exploring and identifying perceived gaps to achieving optimal RUM. The CORUM tool was based on the WHO 12 key interventions to promote RUM. 62 participants took part with most respondents believing their country could improve RUM capacity. This included educational initiatives on the use of clinical guidelines (90%) and the inclusion of problem-based pharmacotherapy in undergraduate curricula and for Continued Professional Development. Key challenges included a lack of regular updates of guidelines, exacerbated by limited funding and a lack of follow-up to monitor adherence to agreed guidelines. RUM could also be enhanced by the development of regional formularies as well as implementing Drug and Therapeutic Committees where these are currently limited. There also needs to be greater co-ordination between RUM and Health Technology Assessment activities, with countries learning from each other. There is an urgent need to improve RUM through improved educational and other activities among European countries, with countries learning from each other. This will involve addressing current challenges and we will be following this up.
Identifiants
pubmed: 32194401
doi: 10.3389/fphar.2020.00144
pmc: PMC7063972
doi:
Types de publication
Journal Article
Langues
eng
Pagination
144Informations de copyright
Copyright © 2020 Gad, Salem, Oortwijn, Hill and Godman.
Références
Indian J Pharmacol. 2010 Apr;42(2):63-4
pubmed: 20711366
Hosp Pract (1995). 2019 Feb;47(1):53-58
pubmed: 29757036
Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72
pubmed: 14960256
Ann Oncol. 2016 Nov;27(11):2134-2136
pubmed: 27502718
Expert Rev Clin Pharmacol. 2018 Dec;11(12):1255-1262
pubmed: 30451035
Appl Health Econ Health Policy. 2013 Feb;11(1):1-3
pubmed: 23329382
Expert Rev Clin Pharmacol. 2015 Jan;8(1):77-94
pubmed: 25487078
Eur J Clin Pharmacol. 2018 Jan;74(1):131-138
pubmed: 29063149
Eur J Clin Pharmacol. 2018 Jul;74(7):971-978
pubmed: 29632961
Philos Ethics Humanit Med. 2014 Mar 29;9:7
pubmed: 24679064
Basic Clin Pharmacol Toxicol. 2014 Sep;115(3):268-76
pubmed: 24528496
Cochrane Database Syst Rev. 2007 Oct 17;(4):CD000409
pubmed: 17943742
PLoS One. 2017 Dec 28;12(12):e0190147
pubmed: 29284064
Lancet Oncol. 2014 Mar;15(3):e119-31
pubmed: 24534293
Front Pharmacol. 2014 Jun 17;5:106
pubmed: 24987370
Basic Clin Pharmacol Toxicol. 2015 Feb;116(2):146-57
pubmed: 25052464
Nature. 2018 Mar 8;555(7695):S26-S29
pubmed: 29517030
Appl Health Econ Health Policy. 2010;8(1):7-24
pubmed: 20038190
Front Pharmacol. 2016 Jul 22;7:197
pubmed: 27516740
Semin Nucl Med. 2019 Mar;49(2):145-152
pubmed: 30819394
Expert Rev Anti Infect Ther. 2017 Oct;15(10):963-972
pubmed: 28922959
Expert Rev Pharmacoecon Outcomes Res. 2010 Feb;10(1):73-85
pubmed: 20121565
Target Oncol. 2018 Dec;13(6):725-733
pubmed: 30446872
Ann Pharmacother. 2011 Jan;45(1):31-8
pubmed: 21205953
J Obes. 2011;2011:459263
pubmed: 21785716
BMJ Open. 2019 Sep 4;9(9):e027059
pubmed: 31488467
Pharmacoeconomics. 2019 Dec;37(12):1469-1483
pubmed: 31535280
BMJ Open. 2015 Dec 29;5(12):e008073
pubmed: 26715477
Expert Rev Respir Med. 2019 Jul;13(7):679-689
pubmed: 31189394
Front Pharmacol. 2014 Jun 10;5:109
pubmed: 24959145
Qual Prim Care. 2009;17(3):179-89
pubmed: 19622268
J Oncol Pract. 2019 Dec;15(12):e1076-e1084
pubmed: 31573829
Basic Clin Pharmacol Toxicol. 2011 Apr;108(4):224-33
pubmed: 21414143
BMC Health Serv Res. 2019 Jul 31;19(1):536
pubmed: 31366363
Int J Qual Health Care. 2019 Jun 1;31(5):338-345
pubmed: 30169688
Eur J Clin Pharmacol. 2013 May;69 Suppl 1:73-8
pubmed: 23640191
JAMA Intern Med. 2018 Dec 1;178(12):1715
pubmed: 30383081
BMC Health Serv Res. 2009 Jan 16;9:12
pubmed: 19149888
Front Public Health. 2018 Dec 05;6:328
pubmed: 30568938
Lancet Oncol. 2014 Mar;15(3):e112-8
pubmed: 24534294
Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):251-261
pubmed: 30696372
BMC Health Serv Res. 2019 Jan 30;19(1):80
pubmed: 30700295
Pharmacoeconomics. 2016 Oct;34(10):967-9
pubmed: 27260615
Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):707-22
pubmed: 21155704
J Comp Eff Res. 2014 Jan;3(1):41-51
pubmed: 24345256
J Pharm Pharm Sci. 2013;16(4):511-29
pubmed: 24210060
Can Pharm J (Ott). 2012 May;145(3):142-146.e2
pubmed: 23509530
Health Policy. 2010 Mar;94(3):221-9
pubmed: 19879009
Int J Technol Assess Health Care. 2017 Jan;33(2):279-287
pubmed: 28641588
Eur J Clin Pharmacol. 2014 Feb;70(2):249-50
pubmed: 24132558
Pharmacoeconomics. 2015 Sep;33(9):905-24
pubmed: 26048353
Lancet. 2009 Jan 17;373(9659):240-9
pubmed: 19042012
BMC Med. 2013 Aug 13;11:179
pubmed: 23941275
Front Pharmacol. 2011 Jan 07;1:141
pubmed: 21833180
Expert Rev Pharmacoecon Outcomes Res. 2009 Feb;9(1):65-83
pubmed: 19371180
BMC Med. 2014 Jun 13;12:98
pubmed: 24927744
J Comp Eff Res. 2019 Sep;8(12):1027-1041
pubmed: 31512925
BMJ Open. 2017 May 2;7(4):e014345
pubmed: 28465306
JBI Database System Rev Implement Rep. 2016 Jun;14(6):42-51
pubmed: 27532648
Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):469-79
pubmed: 21831028
BMJ Open. 2018 Nov 25;8(11):e017572
pubmed: 30478101
Lancet. 2019 Aug 31;394(10200):710
pubmed: 31478486
Front Pharmacol. 2017 Nov 09;8:751
pubmed: 29163151
Expert Rev Pharmacoecon Outcomes Res. 2018 Dec;18(6):655-666
pubmed: 30014725
Eur J Clin Pharmacol. 2008 Dec;64(12):1137-8
pubmed: 18688606
Front Pharmacol. 2018 Sep 03;9:938
pubmed: 30233363
Front Pharmacol. 2013 May 14;4:39
pubmed: 23717279
Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):439-41
pubmed: 22971029
BMC Health Serv Res. 2016 Aug 15;16(a):383
pubmed: 27528247
Pharmacy (Basel). 2016 Oct 28;4(4):
pubmed: 28970408
Front Pharmacol. 2016 Sep 28;7:305
pubmed: 27733828
Expert Rev Clin Pharmacol. 2017 Nov;10(11):1273-1280
pubmed: 28776442
Appl Health Econ Health Policy. 2013 Aug;11(4):383-93
pubmed: 23754677
Oncotarget. 2017 May 9;8(42):71548-71555
pubmed: 29069727
BMC Med Inform Decis Mak. 2015 Oct 08;15:79
pubmed: 26450415
PLoS Med. 2010 Oct 19;7(10):e1000352
pubmed: 20976098
J Am Acad Dermatol. 2017 Feb;76(2):299-308.e16
pubmed: 27693008
Expert Rev Pharmacoecon Outcomes Res. 2013 Feb;13(1):141-51
pubmed: 23402454
BMJ Open. 2017 Sep 27;7(9):e016408
pubmed: 28963287
Ann Rheum Dis. 2017 Feb;76(2):386-391
pubmed: 27307502
BMC Fam Pract. 2011 Aug 10;12:85
pubmed: 21831317
Expert Rev Anti Infect Ther. 2015 May;13(5):665-80
pubmed: 25813839
BMJ. 2010 Sep 22;341:c4715
pubmed: 20861122
BMJ. 2017 Oct 4;359:j4543
pubmed: 28978508
Pharmacoeconomics. 2017 Dec;35(12):1271-1285
pubmed: 28836222
Front Pharmacol. 2017 Aug 23;8:497
pubmed: 28878667
Health Policy. 2012 Aug;106(3):211-24
pubmed: 22694970
Expert Rev Clin Pharmacol. 2019 Feb;12(2):159-168
pubmed: 30407089
Br J Clin Pharmacol. 2019 Feb;85(2):422-431
pubmed: 30423191
J Clin Oncol. 2016 Mar 20;34(9):902-9
pubmed: 26351332
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Comp Eff Res. 2012 Nov;1(6):527-38
pubmed: 24236472
Hosp Pract (1995). 2018 Apr;46(2):77-87
pubmed: 29426263
Pharmacoeconomics. 2017 Oct;35(10):1063-1072
pubmed: 28695544
Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755-8
pubmed: 26368060
Lancet. 2018 Sep 1;392(10149):791-794
pubmed: 30037734
BMC Health Serv Res. 2018 Jul 5;18(1):526
pubmed: 29976180
Appl Health Econ Health Policy. 2009;7(3):137-47
pubmed: 19799468
Front Pharmacol. 2014 Oct 08;5:219
pubmed: 25339902
Pharmacoeconomics. 2016 Jul;34(7):625-7
pubmed: 27194312
Am J Pharm Educ. 2008 Apr 15;72(2):43
pubmed: 18483608
J Econ Perspect. ;29(1):139-62
pubmed: 28441702